Genmab A (GMAB) Cash from Operations Growth (1y) (2019 - 2026)
Genmab A (GMAB) Cash from Operations Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 158.60% |
| 10 | Genmab A | 1.88 Bn | 354.94 Mn | 831.00 Mn | -98.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -98.95% |
| Sep 30, 2025 | 20.08% |
| Jun 30, 2025 | -20.32% |
| Mar 31, 2025 | 31.05% |
| Sep 30, 2020 | -100.00% |
| Dec 31, 2019 | -100.00% |